# Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

> **NCT02567253** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 56 (actual)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Cancer

## Interventions

- **PROCEDURE:** Cytoreductive surgery
- **DRUG:** IPEC with Cisplatin (75mg/m²)
- **DRUG:** IPEC with Cisplatin (100mg/m²)
- **DRUG:** Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)
- **DRUG:** HIPEC with Cisplatin (100mg/m²)

## Key facts

- **NCT ID:** NCT02567253
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-08-25
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567253, "Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02567253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*